Real Chemistry Introduces Iris: An Insights-as-a-Service Platform Delivering Timely Insights on the Obesity Market and the Growing Influence of GLP-1 Therapies
April 30 2024 - 7:00AM
Business Wire
IRIS offers immersive insights reports and live
dashboards designed to help the healthcare industry and other
stakeholders anticipate and identify transformative market events,
and how best to strategically navigate the fast-moving
environment.
Real Chemistry, a leading provider of AI-driven insights and
marketing and communications for the healthcare industry, has
launched IRIS – the only insights-as-a-service platform focused on
helping healthcare leaders and other stakeholders act with clarity
and confidence when transformative healthcare market events emerge.
Fueled by the analysis of billions of data points using Real
Chemistry’s proprietary AI, analytics and insights tools, IRIS
offers a live dashboard and timely market reports. The reports
provide a comprehensive, cross-functional analysis and insights
into what's happening now in the healthcare market and the forces
that could shape what's coming next; including its first detailed
view of the fast-moving GLP-1 agonist obesity market.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240430140657/en/
The IRIS platform offers a multi-dimensional and aggregated view
across market performance, market access dynamics, the policy
landscape, consumer behaviors and clinical milestones. IRIS also
includes unparalleled earned and social media analysis for a
dynamic view of the conversation happening in the marketplace,
which is essential for healthcare companies seeking to enter the
increasingly noisy market.
“If you believe GLP-1 agonists for obesity treatment are just
another class of pharmaceutical products, you need to take a closer
look at the transformation that is unfolding,” said Rita
Glaze-Rowe, President of Transformative Healthcare Markets at Real
Chemistry. “No other therapeutic category has the emotional,
psychological, physical, clinical, cultural and economic impact
that treating obesity brings. This new reality has spurred
behaviors that are pushing and challenging the U.S. healthcare
ecosystem. IRIS is designed to equip leaders with the continuous
data-driven insights they need to understand what is happening and
optimize how they operate within and alongside these
transformations.”
The first market-level report, titled “GLP-1 Agonists: Signals
of a New Era,” explores how the catalyzing forces driving treatment
for obesity, the most relatable condition in the U.S., are leading
to a new analogue for the healthcare industry – one that mirrors
consumer lifestyle industries instead of traditional healthcare
marketing and communication benchmarks. The impact of this could be
far-reaching across the industry and reset how health and
healthcare companies engage with consumers, physicians and
patients.
Key findings from the report include:
- The rise of a new GLP-1 influencer with online behaviors,
content creation momentum and monetization approaches that mirror
what has been seen with the beauty and fashion influencer
community, rather than with healthcare influencers. This new
phenomenon is putting additional strain on an already complex
patient-healthcare provider relationship and creating pressure for
marketing and communication teams to create new ways to engage,
educate and activate.
- Growing consumer-led, online communities are joining forces to
navigate and advise others on managing market impacts, such as
shortages and access. As a result, these communities are
circumventing the traditional ecosystem, creating gaps in
real-world data visibility and adversely impacting the healthcare
provider-patient relationship.
- Currently, there are 119 active GLP-1 agonist clinical trials,
with 53 in Phases 3 or 4. These trials cover more than 60 potential
new disease states for GLP-1 treatment. The potential market entry
of new drugs in five to 10 years means that organizations that are
exploring launching new products will need stronger commercial
readiness strategies to optimize their potential position with
investors.
“Transformative healthcare events can be fluid and can reshape
the healthcare ecosystem, but the question of how deep and wide the
impact will be is what healthcare continues to grapple with in
planning and actions,” said Shankar Narayanan, CEO of Real
Chemistry. “That’s why we’ve made the strategic decision to invest
in this team and platform to help our clients be proactive when new
innovations shake up the market. We’re bringing the best of our
expertise, data and analytics together to help the healthcare
industry stay ahead of the curve and create better patient
experiences in our pursuit to transform healthcare from what it is
to what it should be.”
This report is the first of many from Real Chemistry's new
Transformative Healthcare Markets team of multi-disciplinary
experts. The team’s goal is to help stakeholders understand the
forces creating the healthcare ecosystem’s most disruptive markets,
providing the insights and direction to proactively anticipate and
respond to impacts in near-real-time.
About Real Chemistry
Real Chemistry is a trusted partner to the world’s most
successful life sciences and healthcare companies. As a leading
provider of AI-powered audience analytics and insights, we help the
healthcare industry better understand, reach and engage patients
and professionals using bold ideas to create human-centric
healthcare experiences. Anchored by our culture of innovation and
boundless creativity, our 2,000+ experts across the life sciences,
marketing communications and technology enable modern medical
therapies and those they were designed to help meet and exceed
their potential.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430140657/en/
Media: Lauren Venoy, APR Director, Corporate
Communications LVenoy@RealChemistry.com (904) 874-5814
IRIS Platform: Shelly Cohn, VP, Customer Success
Transformative Healthcare Markets scohn@realchemistry.com (847)
826-6583